Prophylactic Dimenhydrinate for Intraoperative Nausea and Vomiting

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study will be to determine whether an intravenous dose of dimenhydrinate (also known as Gravol), given before the induction of spinal anesthesia, will decrease the incidence of intraoperative nausea and vomiting in patients undergoing Cesarean delivery.

This medication is commonly given during and after the surgery if required, but it is not known whether a preventative dose will decrease the overall incidence of these side effects.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Samuel Lunenfeld Research Institute, Mount Sinai Hospital
• Treatments: Dimenhydrinate

Criteria

Inclusion Criteria:

• All patients undergoing elective Cesarean deliveries under spinal anesthesia.

• All patients who gave written informed consent to participate in this study.

• ASA I and II patients.

• Full term normal pregnancy.

Exclusion Criteria:

• All patients who refuse to give written informed consent.

• All patients who claim allergy or hypersensitivity to dimenhydrinate.

• Patients with history of vomiting within 24 hours prior to Cesarean delivery.

• Patients with history of gastrointestinal or psychiatric diseases and morbid obesity

• Patients receiving any of the following drugs within 24 hours before the study:

opioids, antiemetics, H2 antagonists, phenothiazine and corticosteroids.

• Patients with severe pregnancy induced hypertension